← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Affinergy, Llc
Durham, NC
$38,664,804
Total funding
41
Grants
Funding over time
peak $4.7M · FY2011–24$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$38,664,804 · 41
By mechanism
R44$31,739,200 · 17
R43$6,925,604 · 24
Investigators at Affinergy, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Localized Growth Factor Therapy for Surgical Hernia Repair$1,077,740
R44 · FY2011 · GM
Development of an adipose-derived stem cell isolation matrix$1,025,971
R44 · FY2013 · GM
Point of Care Adult Stem Cell Isolation$958,831
R44 · FY2012 · AR
Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs$913,033
R44 · FY2012 · GM
Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs$910,092
R44 · FY2013 · GM
Bioactive Peptide Coatings for Synthetic Bone Grafts$900,131
R44 · FY2013 · GM
Point of Care Adult Stem Cell Isolation$869,485
R44 · FY2011 · AR
Development of an adipose-derived stem cell isolation matrix$807,976
R44 · FY2012 · GM
Development of an adipose-derived stem cell isolation matrix$789,247
R44 · FY2014 · GM
Bioactive Peptide Coatings for Synthetic Bone Grafts$776,867
R44 · FY2012 · GM
Novel assay to monitor Tacrolimus levels at the point of care$759,336
R44 · FY2019 · AI
Point-of-care device to identify patients at risk for preeclampsia$752,918
R44 · FY2018 · EB
Stem cell-binding peptides for rapid fixation of total hip replacements$749,918
R44 · FY2017 · AR
Peptide conjugation for Co-Delivery of Growth Factors and Stem Cells$747,725
R44 · FY2012 · GM
Stem cell-binding peptides for rapid fixation of total hip replacements$746,272
R44 · FY2018 · AR
Development of a novel clinical assay for measuring everolimus levels$744,006
R44 · FY2019 · AI
A Rapid Point of Care Test for APOL1 Renal Risk Alleles$741,371
R44 · FY2022 · MD
Point-of-care device to identify patients at risk for preeclampsia$736,241
R44 · FY2019 · EB
Novel assay to monitor Tacrolimus levels at the point of care$735,018
R44 · FY2021 · AI
Peptide-coated skin substitutes for the treatment of burn injuries and wounds$734,274
R44 · FY2016 · GM